These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15178911)

  • 1. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.
    Jullien D; Prinz JC; Langley RG; Caro I; Dummer W; Joshi A; Dedrick R; Natta P
    Dermatology; 2004; 208(4):297-306. PubMed ID: 15178911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
    Cather JC; Cather JC; Menter A
    Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator.
    Papp KA
    Drugs Today (Barc); 2004 Nov; 40(11):889-99. PubMed ID: 15645002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efalizumab, a reversible T-cell modulator for psoriasis.
    Shear NH; Langley RG; Ho V
    J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The lymphocyte: protagonism in the new era of the biological therapies].
    Gutiérrez M; Ruiz Carrascosa JC
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():2-8. PubMed ID: 18341848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
    Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
    Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
    J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efalizumab: a biological agent for the treatment of psoriasis.
    Hodulik S; Hadi S
    Rev Recent Clin Trials; 2006 May; 1(2):165-8. PubMed ID: 18473968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
    Leonardi CL; Toth D; Cather JC; Langley RG; Werther W; Compton P; Kwon P; Wetherill G; Curtin F; Menter A
    Dermatology; 2006; 213(3):204-14. PubMed ID: 17033169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New biologic therapies for psoriatic disease.
    Bohjanen KA; Prawer SE
    Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efalizumab.
    Talamonti M; Spallone G; Di Stefani A; Costanzo A; Chimenti S
    Expert Opin Drug Saf; 2011 Mar; 10(2):239-51. PubMed ID: 21214420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efalizumab for the treatment of moderate to severe plaque psoriasis.
    Jordan JK
    Ann Pharmacother; 2005 Sep; 39(9):1476-82. PubMed ID: 15998666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.
    Ng CM; Joshi A; Dedrick RL; Garovoy MR; Bauer RJ
    Pharm Res; 2005 Jul; 22(7):1088-100. PubMed ID: 16028009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hand and foot psoriasis with emphasis on efalizumab.
    Kircik L
    Skin Therapy Lett; 2007 Nov; 12(9):4-7. PubMed ID: 18087658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
    Balato A; La Bella S; Gaudiello F; Balato N
    J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis.
    Frampton JE; Plosker GL
    Am J Clin Dermatol; 2009; 10(1):51-72. PubMed ID: 19170413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts and review of efalizumab in the treatment of psoriasis.
    Leonardi CL
    Dermatol Clin; 2004 Oct; 22(4):427-35, ix. PubMed ID: 15450338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
    Schön MP
    Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.